AIM: This study assessed the ability of visual and quantitative 124-iodine positron emission tomography ((124)I PET) data to detect disseminated iodine-avid lung metastases (DILM) of differentiated thyroid cancer (DTC). MATERIALS AND METHODS: Using "post-therapy" 131-iodine ((131)I) whole-body scintigraphy (TxWBS) and thoracic computed tomography (CT), we retrospectively divided 70 consecutive DTC patients undergoing (124)I PET dosimetry approximately 1 week before (131)I therapy into subgroups positive (n = 7) or negative (n = 63) for DILM, defined as lung metastases visible on TxWBS but not thoracic CT. To determine whether (124)I PET data could distinguish patients with versus without DILM, we compared these data with the TxWBS findings. The (124)I PET data were acquired via whole-body PET scans approximately 24 h after oral administration of (124)I, 24 +/- 2 MBq. Quantitative data comprised absolute lung (124)I activity concentrations and lung-to-background (L/B) (124)I uptake ratios. RESULTS: Only 1/7 DILM-positive patients had visible disseminated lung uptake. Absolute (124)I lung uptake activities overlapped considerably between both groups and did not differ significantly (P = 0.150). Mean L/B ratios, however, differed significantly between the DILM-positive and negative groups (P < 0.001). Nevertheless, L/B ratios overlapped between the groups (0.62-1.37 versus 0.13-0.69). CONCLUSION: Quantitative analysis of (124)I PET data using the L/B ratio is a promising tool to detect patients suspicious for DILM. However, L/B ratios overlapped between the groups to an extent that an unequivocal diagnosis based solely on this criterion was impossible in some patients. In those cases, additional diagnostic tests are necessary for diagnosis.
AIM: This study assessed the ability of visual and quantitative 124-iodine positron emission tomography ((124)I PET) data to detect disseminated iodine-avid lung metastases (DILM) of differentiated thyroid cancer (DTC). MATERIALS AND METHODS: Using "post-therapy" 131-iodine ((131)I) whole-body scintigraphy (TxWBS) and thoracic computed tomography (CT), we retrospectively divided 70 consecutive DTC patients undergoing (124)I PET dosimetry approximately 1 week before (131)I therapy into subgroups positive (n = 7) or negative (n = 63) for DILM, defined as lung metastases visible on TxWBS but not thoracic CT. To determine whether (124)I PET data could distinguish patients with versus without DILM, we compared these data with the TxWBS findings. The (124)I PET data were acquired via whole-body PET scans approximately 24 h after oral administration of (124)I, 24 +/- 2 MBq. Quantitative data comprised absolute lung (124)I activity concentrations and lung-to-background (L/B) (124)I uptake ratios. RESULTS: Only 1/7 DILM-positive patients had visible disseminated lung uptake. Absolute (124)I lung uptake activities overlapped considerably between both groups and did not differ significantly (P = 0.150). Mean L/B ratios, however, differed significantly between the DILM-positive and negative groups (P < 0.001). Nevertheless, L/B ratios overlapped between the groups (0.62-1.37 versus 0.13-0.69). CONCLUSION: Quantitative analysis of (124)I PET data using the L/B ratio is a promising tool to detect patients suspicious for DILM. However, L/B ratios overlapped between the groups to an extent that an unequivocal diagnosis based solely on this criterion was impossible in some patients. In those cases, additional diagnostic tests are necessary for diagnosis.
Authors: M Schlumberger; C Challeton; F De Vathaire; J P Travagli; P Gardet; J D Lumbroso; C Francese; F Fontaine; M Ricard; C Parmentier Journal: J Nucl Med Date: 1996-04 Impact factor: 10.057
Authors: Walter Jentzen; Lutz Freudenberg; Ernst G Eising; Melanie Heinze; Wolfgang Brandau; Andreas Bockisch Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2006-05-09 Impact factor: 5.958
Authors: Hong Song; Bin He; Andrew Prideaux; Yong Du; Eric Frey; Wayne Kasecamp; Paul W Ladenson; Richard L Wahl; George Sgouros Journal: J Nucl Med Date: 2006-12 Impact factor: 10.057
Authors: L S Freudenberg; W Jentzen; R J Marlowe; W W Koska; M Luster; A Bockisch Journal: Exp Clin Endocrinol Diabetes Date: 2007-11 Impact factor: 2.949
Authors: Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger Journal: Eur J Nucl Med Mol Imaging Date: 2016-06 Impact factor: 9.236
Authors: Robert F Hobbs; Richard L Wahl; Martin A Lodge; Mehrbod S Javadi; Steve Y Cho; David T Chien; Marge E Ewertz; Caroline E Esaias; Paul W Ladenson; George Sgouros Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Gauri R Khorjekar; Douglas Van Nostrand; Carlos Garcia; Jeffrey O'Neil; Shari Moreau; Francis B Atkins; Mihriye Mete; Michael H Orquiza; Kenneth Burman; Leonard Wartofsky Journal: Thyroid Date: 2014-06-20 Impact factor: 6.568